Seroxat Filmuhúðuð tafla 20 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

seroxat filmuhúðuð tafla 20 mg

glaxosmithkline pharma a/s - paroxetinum hýdróklóríð - filmuhúðuð tafla - 20 mg

Selexid Filmuhúðuð tafla 400 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

selexid filmuhúðuð tafla 400 mg

karo pharma ab* - pivmecillinamum hýdróklóríð - filmuhúðuð tafla - 400 mg

Selexid Filmuhúðuð tafla 200 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

selexid filmuhúðuð tafla 200 mg

karo pharma ab* - pivmecillinamum hýdróklóríð - filmuhúðuð tafla - 200 mg

Síprox Tafla 250 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

síprox tafla 250 mg

teva b.v.* - ciprofloxacinum hýdróklóríð - tafla - 250 mg

Síprox Tafla 500 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

síprox tafla 500 mg

teva b.v.* - ciprofloxacinum hýdróklóríð - tafla - 500 mg

Trimbow Evrópusambandið - íslenska - EMA (European Medicines Agency)

trimbow

chiesi farmaceutici s.p.a. - beclometasone dipropionate, formóteróli fúmarat tvíhýdrat, Þannig brómíð - lungnasjúkdómur, langvarandi hindrandi - lyf til veikindi öndunarvegi sjúkdómum, - maintenance treatment of asthma, in adults not adequately controlled with a maintenance combination of a long-acting beta2-agonist and high dose of inhaled corticosteroid, and who experienced one or more asthma exacerbations in the previous year. copdmaintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (copd) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2-agonist or a combination of a long-acting beta2-agonist and a long-acting muscarinic antagonist (for effects on symptoms control and prevention of exacerbations see section 5. asthmamaintenance treatment of asthma, in adults not adequately controlled with a maintenance combination of a long-acting beta2-agonist and medium dose of inhaled corticosteroid, and who experienced one or more asthma exacerbations in the previous year.